Insmed announces positive topline results from landmark aspen study of brensocatib in patients with bronchiectasis

—phase 3 study achieves primary endpoint for both dosage strengths of brensocatib with statistically significant and clinically meaningful reduction in frequency of pulmonary exacerbations versus placebo— —treatment with brensocatib also achieves statistical significance on multiple secondary endpoints for both dosage strengths versus placebo— —brensocatib well-tolerated at both dosage strengths— —results from aspen validate dpp1 inhibition as new mechanism of action with potential to address range of neutrophil-mediated diseases— —insmed plans to advance quickly toward u.s. regulatory filing, with anticipated u.s. launch in mid-2025, pending approval— —insmed to host investor call at 8:00 am et on tuesday, may 28, 2024— bridgewater, n.j. , may 28, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive topline results from the aspen study, a global, randomized, double-blind, placebo-controlled phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.
INSM Ratings Summary
INSM Quant Ranking